QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.

Company profile
Ticker
QGEN
Exchange
Website
CEO
Thierry Bernard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QIAGEN NV
SEC CIK
QGEN stock data
News
QIAGEN Reports Purchase Of Majority Stake In BLIRT, No Terms Disclosed
11 May 22
Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance
6 May 22
QIAGEN Continues To Update Its Range Of Automation Solutions With The Launch Of High-sensitive Capillary Electrophoresis Instrument Qiaxcel Connect
4 May 22
Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook
27 Apr 22
Earnings Scheduled For April 27, 2022
27 Apr 22
Press releases
QIAGEN's Eco-Friendlier Products Earn Prestigious ACT Label
19 May 22
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
16 May 22
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
11 May 22
QIAGEN Proposes Expansion of Supervisory Board
11 May 22
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
5 May 22
Calendar
14 Mar 22
24 May 22
31 Dec 22
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2022
59.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 285 |
Opened positions | 41 |
Closed positions | 51 |
Increased positions | 102 |
Reduced positions | 90 |
13F shares | Current |
---|---|
Total value | 6.66B |
Total shares | 134.65M |
Total puts | 244.43K |
Total calls | 1.52M |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Massachusetts Financial Services | 20.51M | $1B |
Davidson Kempner Partners | 9.61M | $517.39M |
Vanguard | 8.05M | $394.44M |
BLK Blackrock | 7.24M | $354.53M |
Capital World Investors | 5.64M | $276.2M |
Wellington Management | 4.86M | $240.38M |
DB Deutsche Bank AG - Registered Shares | 4.13M | $202.32M |
Davidson Kempner Capital Management | 3.5M | $172.43M |
Amundi | 3.5M | $172.54M |
Arrowstreet Capital, Limited Partnership | 3.5M | $171.98M |
Financial report summary
?Competition
Guided Therapeutics • Luminex • Biocept • Exact Sciences • Rosetta Genomics • Veracyte • Nanostring • GenMark Diagnostics • Great Basin Scientific • Lucira HealthContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accredited, Actome, ADLT, AGM, ahead, AKS, ambition, amid, amniotic, AmniSure, Ann, appraisal, Arbor, asserted, Atila, attention, Austria, baseline, Bayer, BD, Becton, Bloomberg, breadth, Campaign, capture, carbon, carryback, CCPA, CDPA, CHIP, climate, CMP, Coalition, Collector, Colorado, commodity, compel, complicating, concealing, Congressional, consumption, copy, counter, CPRA, Crimea, debilitating, defect, defrauding, Depositary, devaluation, Dickinson, diminish, discern, disciplined, divert, DOJ, Donetsk, drawn, driver, durability, dysplasia, Ebeling, eighteen, ERP, ERPD, ethnic, fallout, falsifying, Fed, Female, fluid, FN, friendly, geopolitical, globe, gradual, greatly, GT, hacking, Hamburg, ICE, imposition, improperly, inconsistent, incursion, ineffective, instability, interference, Internet, intervene, intervention, invaded, invasion, ISS, jury, justice, legislature, levied, likewise, live, LTI, Luhansk, Lyme, LymeDetect, magnify, mainstream, Male, MDSAP, MDx, mediation, MGH, military, Mirati, Missouri, moderate, Moscow, MSCI, NAV, naval, neonatal, nurse, OFAC, offense, Omicron, OncXerna, onset, PAXgene, persuade, plastic, Plex, population, practitioner, PreAnalytix, preexisting, pressing, proceed, psychology, QIAsphere, QIAwave, quantity, quick, ransomware, recession, recoupment, recyclability, Reg, reintroduced, resumption, ROM, RSV, ruble, Russian, SBTi, score, secret, seizure, separatist, sequester, shrinking, Singular, spun, STI, studio, succeeded, sued, surrendered, syncytial, Sysmex, terrorist, textual, tied, timeframe, tolerance, traction, tranche, trillion, turmoil, Ukraine, UM, unclassified, unfunded, unlawful, unlicensed, upscaling, USA, Vantage, variant, verdict, video, Virginia, war, warfare, warming, wastewater, XETRA, Zone
Removed:
administering, administratively, advancing, advertisement, anonymized, ban, barcode, begun, Belgium, Beverly, bipartisan, Brexit, Britain, broadened, burdensome, CA, Cambridge, Centrale, century, claimed, Codevelopment, cole, Commissioner, commit, comparison, contemporary, Coventry, crime, database, deadline, discontinued, EBIT, ECP, Eli, eligibility, Ellume, enzyme, faced, Farmer, favour, finalized, fit, forum, gather, GbR, GINA, GPC, HHS, IBS, IMDRF, Immunodiagnostic, immunological, implicated, Indiana, Ingenium, kickback, Laer, leveraged, Lilly, machinery, Manchester, Manila, marked, messenger, metric, Minden, minimal, Minnesota, MO, modernizing, multiplexing, Munich, Nevada, Nondiscrimination, Nonemployee, nonmarketable, obstacle, occupy, offence, Official, OmicSoft, Operon, outlay, outline, penalty, PLC, Postbank, postmarket, practiced, producer, prohibiting, promise, punishable, putting, QCI, quicker, QVA, read, reclassify, reevaluate, referral, referring, regulating, retrospectively, revalued, RGQ, somatic, sovereign, Stark, steering, stranded, talented, task, technically, territory, throughput, Tokyo, twelve, version, violated, waiver, Wroclaw
Financial reports
Current reports
6-K
Current report (foreign)
28 Apr 22
6-K
Current report (foreign)
27 Apr 22
6-K
Current report (foreign)
9 Feb 22
6-K
Current report (foreign)
7 Nov 21
6-K
Current report (foreign)
7 Nov 21
6-K
Current report (foreign)
1 Aug 21
6-K
Current report (foreign)
1 Aug 21
6-K
Current report (foreign)
1 Aug 21
6-K
Current report (foreign)
12 Jul 21
6-K
Current report (foreign)
4 May 21
Registration and prospectus
SC 14D9/A
Tender offer solicitation (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
11 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
7 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
6 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
5 Aug 20
SC 14D9/A
Tender offer solicitation (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
3 Aug 20
Proxies
No filings
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
14 Mar 22
SD
Conflict minerals disclosure
26 Mar 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
4 Mar 21
SD
Conflict minerals disclosure
29 Mar 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
1 Mar 20
UPLOAD
Letter from SEC
1 Oct 19
CORRESP
Correspondence with SEC
24 Sep 19
UPLOAD
Letter from SEC
15 Sep 19
SD
Conflict minerals disclosure
7 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 19
Ownership
SC 13G/A
QIAGEN / MASSACHUSETTS FINANCIAL SERVICES ownership change
2 Feb 22
SC 13G/A
QIAGEN / BlackRock ownership change
27 Jan 22
SC 13G
QIAGEN / BlackRock ownership change
25 Jan 22
SC 13G/A
QIAGEN / MASSACHUSETTS FINANCIAL SERVICES ownership change
11 Feb 21
SC 13G/A
QIAGEN / WELLINGTON MANAGEMENT ownership change
3 Feb 21
SC 13G/A
QIAGEN / BlackRock ownership change
26 Jan 21
SC 13D/A
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
22 Jan 21
SC 13D
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
3 Aug 20
SC 13G/A
Qiagen NV
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
Reddit threads
Daily Discussion Thread - April 27th, 2022
27 Apr 22
Daily Discussion Thread - April 26th, 2022
26 Apr 22
Daily Discussion Thread - April 25th, 2022
25 Apr 22
Daily Discussion Thread - February 8th, 2022
8 Feb 22
Daily Discussion Thread - February 7th, 2022
7 Feb 22
Morning Update for Monday, 11/29/21
29 Nov 21
What stocks are strong plays with or without COVID?
27 Nov 21
Stock Watch List November 3, 2021
3 Nov 21
Daily Discussion Thread - November 3rd, 2021
3 Nov 21
Daily Discussion Thread - November 2nd, 2021
2 Nov 21